# Akanda Corp. (AKAN)

> Source: Nexqual · https://nexqual.com/AKAN · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, Akanda Corp. (AKAN), nexqual.com/AKAN" · informational, not investment advice.

**Price:** USD 1.01 (-12.17% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 1.15 · day 1.01–1.28 · 52w 1–78.9 · market cap $2.7M · NCM

## Key facts
- Analysts: None.
- Total return with dividends: 1Y -98.0% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2022-03-14) |
|---|---|---|
| Total return | -98.0% | -100.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -98.0% | -93.9% |
| Volatility (annualized) | 215.8% | 184.5% |
| Max drawdown | -98.2% (May 2026→Oct 2026) | -100.0% (Apr 2022→Oct 2026) |

## Peers (Drug Manufacturers - Specialty & Generic)
SUPN (Supernus Pharmaceuticals, Inc.) USD 40.7 -3.26% · BHC (Bausch Health Companies Inc.) USD 6.44 -0.77% · HCM (HUTCHMED (China) Limited) USD 14.36 +0.56% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.2 -4.80% · RGC (Regencell Bioscience Holdings L) USD 7.67 -21.81% · LQDA (Liquidia Corporation) USD 42.65 +7.46%

## More
Full page: https://nexqual.com/AKAN · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in AKAN's own 20-F filed 2026-06-09 (https://www.sec.gov/Archives/edgar/data/1888014/000121390026066800/ea0288681-20f_akanda.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Halo Collective | "In September 2021, we entered into a share purchase agreement with Halo, a publicly-traded," |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |